According to the type of CD19+ B cells, CD4+ T cells, pDCs and PBMC, 14300 DEGs in MS patients before and after the application of Fingolimod and IFN-β were obtained according to the standards of P < 0.05 and FC > 1.2 or 0 < FC < 1/1.2 (CD19+ B cells: 1164 DEGs; CD4+ T cells: 13201 DEGs; pDCs: 668 DEGs; PBMC: 593 DEGs) (Table 2, Supplementary Table S2). This evidence concerns the gene CD19 and myeloid sarcoma.